Essa Pharma Soars on Clinical Update for Prostate Cancer Treatment

“The maturing data from the Phase 1 dose escalation study evaluating masofaniten in combination with enzalutamide continue to demonstrate that the combination is well tolerated, accompanied by deep and durable reductions in circulating prostate-specific antigen (“PSA”) levels.

David Parkinson, MD, President and CEO of ESSA

“While the data are still immature, the durability of the PSA responses is encouraging with a median time to PSA progression currently at 16.6 months. The Phase 2 dose expansion head-to-head portion of the study is underway and is designed to evaluate the proportion of patients with a PSA decline on combination therapy compared to single agent enzalutamide. We look forward to evaluating the potential long-term benefits of masofaniten in patients with metastatic castration-resistant prostate cancer and to providing future updates.”

David Parkinson, MD, President and CEO of ESSA